Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Iranian Foreign Ministry: Reimposing sanctions on Iran is illegal
Occupied Palestine: Israeli occupation forces raid homes during a raid on the village of Al-Burj, south of al-Khalil
Hamas spokesperson Hazem Qassem: The movement remains committed to implementing the ceasefire agreement through the handover of another Israeli captive’s body earlier this evening
Al-Arida to Al Mayadeen: We were deprived of all means of communication, and we were isolated from the other detainees so as not to receive any piece of information
Freed prisoner and leader of Operation Freedom Tunnel, Mahmoud al-Arida, to Al Mayadeen: Were it not for the pro-Resistance media, the situation of the isolated detainees would have been catastrophic
Iranian Foreign Ministry: The sanctions reinstated by the E3 are non-binding, and we deem them illegal
Iranian Foreign Ministry: Iran, Russia, and China will send a letter to the United Nations and the Security Council tomorrow confirming the expiration of Resolution 2231 and the end of sanctions
Local Afghan sources: Pakistani airstrikes hit the Arghun district of Paktika province, southeastern Afghanistan, after the ceasefire expired
Hamad to Al Mayadeen: We will return the bodies and abide by the agreement we approved, but what is happening now is an attempt by "Israel" to exert more pressure
Hamad to Al Mayadeen: The issue of the [Israeli] bodies is complex and requires time, especially since the occupation changed the features of Gaza, which we explained to the mediators

Alzheimer's drug approval optimistic amid promising results

  • By Al Mayadeen English
  • Source: Agencies
  • 17 Jul 2023 23:44
3 Min Read

Following clinical trial results, another Alzheimer's drug proven to slow cognitive decline is one step closer to US approval.

  • x
  • A sign for Eli Lilly & Co. outside their headquarters in Indianapolis on April 26, 2017. New research shows another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening. (AP)
    A sign for Eli Lilly & Co. outside their headquarters in Indianapolis on April 26, 2017. (AP)

As a consequence of clinical trial findings that were published in a reputable publication on Monday, a second Alzheimer's medication that has been shown to reduce cognitive loss moved one step closer to US approval.

After years of little advancement in the field, many experts have welcomed the results as significant advances. However, others have advised caution, characterizing the advantages as limited while highlighting the high prices and risks of life-threatening side effects.

A study published in the Journal of the American Medical Association (JAMA) found that the medicine donanemab reduced the progression of symptoms over an 18-month period by 35% in comparison to placebo in approximately 1,200 persons with early-stage Alzheimer's disease.

Read: 19-year-old Chinese man becomes youngest patient with Alzheimer's

Results from cognitive tests and participants' capacity to complete daily tasks were used to gauge this. Drugmaker Eli Lilly, which said it anticipates regulatory action in the United States by the end of the year, produces the medication, which is administered intravenously every four weeks.

The release of the new research coincides with the US Food and Drug Administration's decision to allow Leqembi, a medication created by Biogen and Eisai, to be covered by Medicare, the nation's sponsored insurance program for the elderly.

Both function by focusing on the protein amyloid beta, which damages cognition when it builds up in the brain.

Related News

UN report reveals cocaine in upward trend, meth market expands

288 people arrested by Europol in massive dark web crackdown

"These first-generation drugs are by no means perfect, but represent an important breakthrough," interim director of the UK Dementia Research Institute, Giles Hardingham, said in a statement.

However, he added that it was equally crucial to understand that Alzheimer's is a complex illness and that amyloid beta was merely one factor in its development.

However, Eric Widera of the University of California, San Francisco, and colleagues argued that it was too early to conclude that the new medications would be helpful in the long run. Such opinions appeared in an editorial that was published alongside the new results in JAMA.

They claimed that Donanemab and Leqembi, also known as lecanemab, do not treat Alzheimer's disease but rather cause "slightly less worsening" in patients.

"The modest benefits would likely not be questioned by patients, clinicians, or payers if amyloid antibodies were low risk, inexpensive, and simple to administer. However, they are none of these," the authors wrote.

Patients will still be responsible for thousands of dollars in out-of-pocket expenses even after Medicare covers 80% of the expenditures.

Additionally, three deaths that were most likely brought on by the therapies that cause brain bleeds occurred in the investigations of donanemab and Leqembi.

Given that anti-amyloid therapies also speed up brain atrophy, research indicates that it will be critical to gather more information as the treatments enter the real world to determine whether they continue to decrease cognitive decline past 18 months or if they have the opposite effect.

Additionally, since 96% of the patients in the donanemab trial were white despite the fact that Black and Latino persons had a much greater prevalence of Alzheimer's, this means that important demographics still remain understudied.

  • Eli Lilly
  • Alzheimer's Disease
  • Drug

Most Read

Iran strikes secret Israeli-US bunker under Tel Aviv high-rise

Tel Aviv high-rise struck by Iran hid Site 81, secret US-Israeli base

  • Politics
  • 14 Oct 2025
Palestinian journalist Saleh al-Jaafarawi in an undated image in Gaza, occupied Palestine (Social media)

Gaza Palestinian journalist Saleh al-Jafarawi killed by collaborators

  • Politics
  • 12 Oct 2025
drop site

New report details extensive Israeli arson in Gaza after ceasefire

  • Politics
  • 13 Oct 2025
Illustration of fists breaking shackles, representing the liberation of Palestinian detainees from Israeli prisons. (Illustrated by: AL Mayadeen English/Batoul Chamas)

4 prominent Palestinian detainees to be freed: Who are they?

  • Palestine
  • 13 Oct 2025

Coverage

All
War on Gaza

Read Next

All
Residents remove debris from a house damaged by Wednesday's two drone strikes, in Kabul, Afghanistan, Thursday, Oct. 16, 2025 (AP)
Politics

Afghanistan-Pakistan negotiations to begin in Doha: Exclusive

Palestine Action wins court fight to challenge UK terror ban
Politics

Palestine Action wins court fight to challenge UK 'terror' ban

John Bolton surrenders after classified documents indictment
Politics

John Bolton turns himself in after classified documents indictment

GSF, GMTG slams EU over complicity in Gaza genocide
Politics

GSF, GMTG slam EU over complicity in crimes against Palestinians

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS